A study of patients with stable angina and moderate left ventricular systolic dysfunction has shown that the addition of ivabradine to bisoprolol produced additional anti-anginal and anti-ischaemic effects that were not achieved with up-titration of bisoprolol.
1 This indicative study is of importance to clinicians as they are frequently faced with patients on β-blockers who are not able to tolerate the full target dose, as defined from evidencebased clinical trials.
Ivabradine is a novel agent that reduces heart rate (HR) by selective and specific inhibition of the I f current in sino-atrial cells, leading to prolongation of the slow diastolic depolarisation phase of the action potential.
Placebo-controlled studies in angina patients have shown that ivabradine improves exercise tolerance, lengthens time to ischaemia, and has anti-anginal and anti-ischaemic efficacy similar to that of atenolol or amlodipine. The ASSOCIATE study in stable angina patients receiving the beta-blocker atenolol has demonstrated that ivabradine reduces HR and improves exercise capacity (Fig. 1 ).
This study, presented at the ACC congress, included 29 patients with chronic stable angina (class II) who had had a myocardial infarction more than three months before and had moderate left ventricular systolic dysfunction on stable therapy, including bisoprolol 5 mg once daily. Therapy included aspirin, and statins enalapril and furosemide in cases with congestive heart failure.
Over a period of two months, resting heart rate was reduced in both groups to similar levels (60 bpm). However more patients in the ivabradine-treated group (7.5 mg twice daily) showed improvements in angina and more patients moved from angina class II to angina class I than those who received the up-titrated bisoprolol dose (10 mg once daily). Importantly, walking distance and exercise tolerance improved in the ivabradine group while no improvement occurred in the bisoprolol-treated group. aCCord liPid study results strengthen guideline approach of adding fenofibrate to therapy of dyslipidaemic type 2 diabetic patients Type 2 diabetic patients treated with statins but still experiencing elevated serum levels of triglycerides (2.3 mmol/l or higher) and low HDL cholesterol (0.8 mmol/l or lower), a pre-specified subgroup, benefited from the addition of fenofibrate to their treatment regimen. Risk of cardiovascular events was reduced by 31% in those patients, translating to a need-to-treat 20 patients for five years to prevent one cardiovascular event.
1 Prof Frank Sacks, Harvard School of Public Health and Brigham and Women's Hospital, Boston, USA pointed out that the ACCORD LIPID study has reinforced the residual-risk hypothesis. 'Interestingly, those patients whose LDL cholesterol was below 3 mmol/l, essentially at target, showed a tendency to receive greater benefit from the addition of fenofibrate.
Importantly, the atherogenic dyslipidaemia group was a pre-specified group in this trial.' 'Previous studies had raised possible concerns about the importance of the observed increase in serum creatinine levels in patients on fenofibrate. The ACCORD LIPID trial has shown convincingly that fenofibrate is safe, with no significant difference in the incidence of
